Timely Data Resources, Inc., Sep 2011, Pages: 13
websites. Sources and references are provided.
The OvarianCancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages
Timely Data Resources, Inc., Oct 2010, Pages: 12
The OvarianCancer Disease and Therapy Review provides incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information on diagnosis, and an overview
Datamonitor, Dec 2010, Pages: 25
Incident cases of ovariancancer will increase across the seven major healthcare markets between 2010 and 2019. In all markets, these increases will be primarily due to the underlying population age
AMID Co., April 2009, Pages: 243
Chinas demand for OvarianCancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines Chinas
Medpredict, Feb 2010, Pages: 146
Ovariancancer is only one tenth as common as breast cancer, but the mortality associated with ovariancancer is higher. There are 250,000 new cases diagnosed each year in the US, and at least 15
Informa Healthcare, Oct 2010, Pages: 460
This comprehensive surgical text, has been updated and expanded and includes the important techniques essential for the effective management of ovariancancer, with particular emphasis on providing
Global Industry Analysts, Inc., Feb 2006, Pages: 248
This report analyzes the worldwide markets for OvarianCancer Therapeutics in Millions of US$. The major product segments analyzed are Localized OvarianCancer Therapeutics, Metastatic Ovarian
Fore Pharma, Jan 2012, Pages: 13
Fore Pharma’s latest report ‘Global OvarianCancer Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global ovariancancer drug
Fore Pharma, Aug 2011, Pages: 13
Fore Pharma’s latest report ‘Global OvarianCancer Drug Pipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global ovariancancer drug
Bioseeker, Feb 2011
With nearly 60,000 cases of ovariancancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication
GlobalData, Dec 2010, Pages: 55
OvarianCancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “OvarianCancer Therapeutics
GBI Research, Nov 2011, Pages: 123
GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in OvarianCancer Trials Exceed Other
Decision Resources, Inc., July 2006, Pages: 25
Worldwide, ovariancancer (CaO) is the leading cause of death from gynecological cancer and the fourth most common cause of cancer death in women. In 2006, according to the American Cancer Society
Datamonitor, July 2010, Pages: 93
Introduction
Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovariancancer. The high level of unmet need, coupled with the large size
Life Science Analytics, March 2011, Pages: 656
OvarianCancer Therapy Area Pipeline Report contains detailed information on the ovariancancer drug pipeline. This report provides insight into the pipeline status of ovariancancer drugs
Informa Healthcare, Oct 2010, Pages: 460
This comprehensive surgical text, has been updated and expanded and includes the important techniques essential for the effective management of ovariancancer, with particular emphasis on providing
Global Markets Direct, Jan 2011, Pages: 286
OvarianCancer - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'OvarianCancer - Pipeline Review, Q1 2011', provides an overview of the OvarianCancer therapeutic pipeline. This report
